Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.
AuthorsLedermann, J A
Jayson, Gordon C
Spanswick, V J
Rustin, G J S
James, L E
Hartley, J A
AffiliationUCL Hospitals, UCL Cancer Institute, London, United Kingdom. firstname.lastname@example.org
MetadataShow full item record
AbstractBACKGROUND: The potential of gemcitabine to interact with carboplatin was explored in a phase II trial in platinum-resistant ovarian cancer. Peripheral blood lymphocytes were sampled after drug administration to measure DNA interstrand cross-link formation and repair. PATIENTS AND METHODS: Forty patients received carboplatin target area under concentration-time curve (AUC 4) followed by gemcitabine 1,000 mg/m(2) with a second dose of gemcitabine on day 8. Peripheral blood lymphocytes were obtained in 12 patients before and at intervals during the first cycle of chemotherapy. DNA cross-link formation and repair (unhooking) were measured by the single-cell gel electrophoresis (comet) assay following ex vivo incubation. RESULTS: The global response rate was 47% (Response Evaluation Criteria in Solid Tumors rate, 29%; CA125 rate, 63%). Delays in treatment were seen in 24% of cycles largely due to myelosuppression; 15% of day 8 administration was omitted. Peak carboplatin-induced DNA cross-linking was seen by 24 hours. Significant reduction was seen in the repair of in vivo carboplatin-induced DNA cross-links following administration of gemcitabine. CONCLUSION: An enhanced activity of carboplatin in platinum-resistant ovarian cancer may be due to synergy with gemcitabine through inhibition of repair of DNA cross-links. Future studies should explore coadministration of these drugs, as this may be a more effective schedule.
CitationInhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer. 2010, 16 (19):4899-905 Clin Cancer Res
JournalClinical Cancer Research
- Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples.
- Authors: Spanswick VJ, Lowe HL, Newton C, Bingham JP, Bagnobianchi A, Kiakos K, Craddock C, Ledermann JA, Hochhauser D, Hartley JA
- Issue date: 2012 Sep 28
- Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer.
- Authors: Stefanou DT, Bamias A, Episkopou H, Kyrtopoulos SA, Likka M, Kalampokas T, Photiou S, Gavalas N, Sfikakis PP, Dimopoulos MA, Souliotis VL
- Issue date: 2015
- The problem with platinum.
- Authors: Holmes D
- Issue date: 2015 Nov 26
- Gemcitabine and vinorelbine combination in platinum-sensitive recurrent ovarian cancer.
- Authors: Ferrero A, Logrippo V, Spanu PG, Fuso L, Perotto S, Daniele A, Zola P
- Issue date: 2009 Dec
- Carboplatin/gemcitabine alternating with carboplatin/pegylated liposomal doxorubicin and carboplatin/cyclophosphamide in platinum-refractory/resistant paclitaxel - pretreated ovarian carcinoma.
- Authors: Pectasides D, Pectasides E, Papaxoinis G, Psyrri A, Pliarchopoulou K, Koumarianou A, Macheras A, Athanasas G, Xiros N, Economopoulos T
- Issue date: 2010 Jul